Dalton Pharma expands pharmaceutical manufacturing services

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

This newly created department is comprised of highly experienced and educated teams. Dalton's analytical, process and formulation scientists are equipped with advanced technology and infrastructure to provide clients with the expertise required to move virtually all types of molecules from development to commercialization in various types of dosage forms. Dosage forms include: sterile and non-sterile liquids, solids, semi-solids and lyophilized formulations (small chemical molecules, proteins and peptides, monoclonal antibodies and high-potency actives).

"Dalton continues to be at the forefront of research, technology and innovation to accelerate our clients' drug development programs. The addition of Formulation Services to our integrated pharmaceutical development capabilities allows us to offer complete drug development and manufacturing of novel pharmaceutical products. Our investment in state of the art capsule filling technology is one of many examples of how we respond to our clients' needs. We have also expanded our Analytical Services to serve our formulation development experts and as a result now offer dissolution testing and particle size distribution testing in our FDA compliant, Health Canada approved analytical testing laboratories," said Peter Pekos, President and CEO of Dalton Pharma Services.